stockrowWarby Parker Inc.
WRBY Healthcare Medical Instruments & Supplies
Warby Parker Inc.’s revenue for fiscal 2025 (year ended December 2025) was $871.9 million, up 13.0% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −20.0%
- Free cash flow
- −30.3%
Quarter to September 2026, against a year earlier
Follow WRBY
Alert me
Warby Parker Inc. (WRBY) Return on assets
Warby Parker Inc.'s return on assets over the twelve months to 30 September 2026 was 1.00%, up 0.8 percentage points from fiscal 2025 (0.23%). Over the past ten years it has ranged from −35.6% (fiscal 2021) to 0.23% (fiscal 2025) — the current reading is the highest in ten years. That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 0.23% | 3.47 |
| FY2024 | −3.24% | 7.76 |
| FY2023 | −11.0% | 10.87 |
| FY2022 | −21.9% | 13.69 |
| FY2021 | −35.6% | (10.41) |
| FY2020 | −25.2% | (25.15) |
| FY2019 | 0.00% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LMAT LeMaitre Vascular, Inc. compare | 10.1% |
| STVN Stevanato Group S.p.A. compare | 5.50% |
| ATRC AtriCure, Inc. compare | 2.20% |
| ICUI ICU Medical, Inc. compare | 1.50% |
| WRBY Warby Parker Inc. | 1.00% |
| XRAY DENTSPLY SIRONA Inc. compare | −2.23% |
| AZTA Azenta, Inc. compare | −6.31% |
| KMTS Kestra Medical Technologies, Ltd. compare | −48.9% |
| PLSE Pulse Biosciences, Inc compare | −54.0% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on WRBY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement